姓名：朱丽君

研究员、生物药剂学与药物动力学教研室副主任、中药学博士生导师

简介：广东省杰青、广州市珠江科技新星

教育经历

[1]2009.9-2012.6南方医科大学-博士

[2]2005.9-2008.6中山大学-硕士

[3]2001.9-2005.6湖南中医药大学-学士

工作经历

[1]2021.5-至今新葡的京集团35222vip-研究员

[2]2015.12-2021.4新葡的京集团35222vip-副研究员

[3]2015.5-2015.10美国休斯顿大学-访问学者

[4]2014.6-2015.11新葡的京集团35222vip-助理研究员

[5]2012.7-2014.5广州医科大学-博士后

研究方向：中药药代动力学及调控机制

研究领域：药物动力学

联系方式：zhulijun@gzucm.edu.cn

研究课题

[1]国家自然科学基金面上项目，82574681，UGT酶探针预测伊立替康化疗重度迟发性腹泻的药代动力学机制及黄芩片治疗作用，2026/01-2029/12，48万元，在研，主持

[2]中医证候全国重点实验室开放课题面上项目，SKLKY2024B0003，经典名方小柴胡汤调控β-GUS构象变化抗伊立替康腹泻的物质基础及分子机制，2025/01-2026/12，10万元, 主持

[3]广州市重点研发计划项目，2024B03J1281，基于潜在质量标志物“PK-TD/PD”研究的附子新质量控制技术建立与应用，2024/01-2026/12，50万元, 主持

[4]广东省自然科学基金杰出青年项目，2022B1515020079，基于“UGT-ET”处置研究小柴胡汤防治伊立替康化疗腹泻的药效及机制，2022/01-2025/12，100万元, 主持

[5]国家自然科学基金重点国际（地区）合作与交流项目，81961128028，经典中药方剂小柴胡汤阻抗伊立替康肠毒性的疗效及药代动力学机制，2020/01-2024/12，300万元，主持

[6]国家自然科学基金面上项目，81874343，基于“化学-PD/PK”的附子质量标志物发现、确证及其调控毒效的分子机制研究，2019/01-2022/12，57万元，主持

[7]广州市科技计划项目珠江科技新星专题，201806010199，基于UGT代谢酶和外排转运蛋白偶联作用的秦皮香豆素类活性成分及其衍生物体内处置特征及机理研究，2018/04-2021/03，30万元，主持

[8]国家科技重大专项课题，2017ZX09301051，组分结构中药新品种奥斯替宝研发及其关键创新技术，2017/01-2020/12，70万元，子课题负责人

[9]国家自然科学基金青年项目，81603379，中药秦皮及其香豆素类活性成分的肝肠处置及调控机制，2017/01-2019/12，17万元，主持

[10]广东省自然科学基金博士科研启动项目，2014A030310417，外排转运蛋白和CYP酶阻抗附子中乌头生物碱毒性的作用及分子机制，2014/10-2017/10，10万元，主持

[11]中国博士后科学基金，2013M542166，α1D-AR拮抗剂YM03对映异构体和外消旋体吸收代谢研究，2013/06-2014/06，5万元，主持

主编或参编教材及著作

[1]刘中秋，李川主编，朱丽君副主编, 《中药药代动力学原理与方法》,科学出版社, ISBN：978-7-03-079120-7, 2025.01.

[2]梅全喜，李楠主编，郑川，杨光义，梁奇，侯强平，黄勤挽，陈琴华，张定堃，朱丽君副主编, 《附子的研究与应用》,中国中医药出版社, ISBN：978-7-5132-8508-7, 2023.

[3]刘中秋主编，朱丽君副主编, 《中药药代动力学理论与应用》,科学出版社, ISBN：978-7-03-069269-6, 2021.

[4]奉建芳、毛声俊、冯年平、王建新主编，朱丽君编委，主编第十章：中药制剂等效性探讨，《现代中药制剂设计》,中国医药科技出版社，ISBN：978-7-5214-1762-3, 2020.

[5]Zhu LJ, Lu LL, Wang SWJ, Wu JJ, Shi J, Yan TM, Xie C, Li Q, Hu M and Liu ZQ, Chapter 11— Oral Absorption Basics: Pathways and Physicochemical and Biological Factors Affecting Absorption, in “Developing Solid Oral Dosage Forms: Pharmaceutical Theory and Practice” (Edited by Qiu YH, Chen YS, Zhang G, Yu L, and Mantri RV), 2nd Edition, Publisher: Mica Haley, Pages: 297-329, Page Count 1176, eBookISBN: 9780128026373, Hard cover ISBN：9780128024478, Imprint: Academic Press, 11.28, 2016.http://doi.org/10.1016/B978-0-12-802447-8.00042-X

代表性论文论著

[1]Weiying Chen^#, Xiang Luo^#, Wentao Li, Xiaocui Li, Ying Wang, Rong Zhang, Bo Liu, Lijun Zhu^*, Zhongqiu Liu^*, Yuanyuan Cheng^*. Uncovering the active ingredients of Xinbao pill against chronic heart failure: A chemical profiling, pharmacokinetics and pharmacodynamics integrated study. Journal of Ethnopharmacology. 2025; 342: 119418. doi: 10.1016/j.jep.2025.119418

[2]Xiaocui Li^#, Qi Liang^#, Caiyan Wang, Huawei Qiu, Tingting Lin, Wentao Li, Rong Zhang, Zhongqiu Liu, Lijun Zhu^*. Role of P-glycoprotein in Regulating the Efficacy, Toxicity and Pharmacokinetics of Yunaconitine. Current Drug Metabolism. 2024;25(5):317-329.

[3]Caiyan Wang^#, Xiaojun Teng^#, Chuang Wang, Binjie Liu, Runze Zhou, Xueyu Xu, Huawei Qiu, Yu Fu, Rongjin Sun, Zuhui Liang, Rong Zhang, Zhongqiu Liu^*, Lin Zhang^*, Lijun Zhu^*. Insight into the mechanism of Xiao-Chai-Hu-Tang alleviates irinotecan-induced diarrhea based on regulating the gut microbiota and inhibiting Gut β-GUS. Phytomedicine.2023. 120: 155040.

[4]Xiaocui Li, Weiqing Hou, Tingting Lin, Jiadong Ni, Huawei Qiu, Yu Fu, Zhongxiang Zhao, Caihua Yang, Na Li, Hua Zhou, Rong Zhang, Zhongqiu Liu, Ling Fu^*, Lijun Zhu^*. Neoline, fuziline, songorine and 10-OH mesaconitine are potential quality markers of Fuzi: In vitro and in vivo explorations as well as pharmacokinetics, efficacy and toxicity evaluations. Journal of Ethnopharmacology. 303 (2023) 115879.

[5]Xiaocui Li^#, Yu Fu^#, Huawei Qiu, Xueyu Xu, Tingting Lin, Weiqing Hou, Weiying Chen, Rong Zhang, Zhongqiu Liu, Lijun Zhu^*. Clinical poisoning events involving yunaconitine may be highly correlated with metabolism-based interactions: A critical role of CYP3A4. Food and Chemical Toxicology. 2023 (179): 113989

[6]Xiaocui Li, Xiaojun Ou, Jiadong Ni, Yihong Xu, Huilin Zuo, Yu Fu, Caihua Yang, Zhongxiang Zhao, Na Li, Hua Zhou, Rong Zhang, Zhongqiu Liu, Ling Fu^*, Lijun Zhu^*. Bulleyaconitine A is a sensitive substrate and competitive inhibitor of CYP3A4: One of the possible explanations for clinical adverse reactions. Toxicology and Applied Pharmacology. 445(2022) 116024.

[7]Yuanyuan Liu^#, Yiyan Lu^#, Xiaoyan Li, Zerong Zhang, Lizhu Sun, Ying Wang, Zhuoru He, Zhongqiu Liu^*, Lijun Zhu^*, Ling Fu^*. Kaempferol suppression of acute colitis is regulated by the efflux transporters BCRP and MRP2. European Journal of Pharmaceutical Sciences. 179 (2022) 106303. PMID: 36252521

[8]Xiaocui Li^#, Xiaowen Ou^#, Guangkuo Luo, Xiaojun Ou, Yusha Xie, Mengdi Ying, Wei Qu, Huilin Zuo, Xiaoxiao Qi, Ying Wang, Zhongqiu Liu^*, Lijun Zhu^*. Mdr1a, Bcrp and Mrp2 regulate the efficacy and toxicity mesaconitine and hypaconitine by altering their tissue accumulation and in vivo residence. Toxicology and Applied Pharmacology. 2020, 409: 115332

[9]Xiaocui Li, Yushan Xie, Wei Qu, Xiaojun Ou, Xiaowen Ou, Chuang Wang, Xiaoxiao Qi, Ying Wang, Zhongqiu Liu^*, Lijun Zhu^*. Breast cancer resistance protein and multidrug resistance protein 2 mediate the disposition of leonurine-10-O-β-glucuronide. Current Drug Metabolism.2020, 21(13): 1060-1067

[10]Rongjin Sun^#, Lijun Zhu^#, Li Li, Wenjie Song, Xia Gong, Xiaoxiao Qi, Ying Wang, Romi Ghose, Song Gao*, Ming Hu*, Zhongqiu Liu*. Irinotecan-mediated diarrhea is mainly correlated with intestinal exposure to SN-38: Critical role of gut Ugt. Toxicology and Applied Pharmacology. 2020, 398: 115032

[11]Lin Zhang^#, Lijun Zhu^#, Wei Qu, Fang Wu, Ming Hu, Wei Xie, Zhongqiu Liu^*, Caiyan Wang^*. Insight into Tartrate inhibition patterns in vitro and in vivo based on cocrystal structure with UDP-glucuronosyltransferase 2B15. Biochemical Pharmacology, 2020, 172: 113753

[12]Yuhuan Li, Wenjie Song, Xiaojun Ou, Guangkuo Luo, Yushan Xie, Rongjin Sun, Ying Wang, Xiaoxiao Qi, Ming Hu, Zhongqiu Liu^*, Lijun Zhu^*. Breast cancer resistance protein and multidrug resistance protein 2 determine the disposition of esculetin-7-O-glucuronide and 4-Methylesculetin-7-O-glucuronide. Drug Metablism & Disposition. 2019, 47 (3): 203-214

[13]Yuhuan Li, Linlin Lu, Liping Wang, Wei Qu, Wenqin Liu, Yushan Xie, Hongming Zheng, Ying Wang, Xiaoxiao Qi, Ming Hu^*, Lijun Zhu^*, Zhongqiu Liu^*. Interplay of efflux transporters with glucuronidation and its impact on subcellular aglycone and glucuronide disposition: a case study with kaempferol. Molecular Pharmaceutics. 2018, 15(12): 5602-5614.

其他代表性业绩

专利

[1]朱丽君，刘中秋，李小翠，倪家栋，许仪红，傅愉，区晓君. 附子灵在制备治疗关节炎药物中的应用. 专利号：202111649116.4，授权日：2023年6月16日。

[2]朱丽君，刘中秋，许仪红，李小翠，黄秋珍，倪家栋，傅愉，区晓君. 塔拉萨敏在制备治疗关节炎药物中的应用. 专利号：202111649118.3，2023年6月16日。

获奖

[1]基于生物利用度屏障的中药及复方功效评价方法的创新及应用，2019年广东省科技进步奖一等奖，获奖人：刘中秋、郭永周、卢琳琳、朱丽君、郭思伟、吴锦俊、张嘉杰、夏笔军、蔡荣钦、王莹、王立萍、吴鹏、段礼新、戚笑笑、黄秋菊。